These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 32967612)

  • 21. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.
    Gillmore JD; Reilly MM; Coats CJ; Cooper R; Cox H; Coyne MRE; Green AJ; McGowan R; Moody WE; Hawkins PN
    Adv Ther; 2022 Jun; 39(6):2292-2301. PubMed ID: 35419651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
    Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
    Adams D; Algalarrondo V; Polydefkis M; Sarswat N; Slama MS; Nativi-Nicolau J
    Orphanet J Rare Dis; 2021 Oct; 16(1):411. PubMed ID: 34602081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
    Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
    Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromuscular Complications of Systemic Amyloidosis.
    Namiranian D; Geisler S
    Am J Med; 2022 Apr; 135 Suppl 1():S13-S19. PubMed ID: 35104443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
    Sekijima Y
    Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
    J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hereditary and acquired transthyretin-mediated amyloidosis].
    van der Bie MH; Louter L; Boots JMM; van Daele PLA; Klaassen SHC; Hazenberg BPC
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32186825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.
    Galant NJ; Westermark P; Higaki JN; Chakrabartty A
    Clin Sci (Lond); 2017 Mar; 131(5):395-409. PubMed ID: 28213611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.
    Conceição I; Damy T; Romero M; Galán L; Attarian S; Luigetti M; Sadeh M; Sarafov S; Tournev I; Ueda M
    Amyloid; 2019 Mar; 26(1):3-9. PubMed ID: 30793974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidisciplinary Approaches for Transthyretin Amyloidosis.
    Koike H; Okumura T; Murohara T; Katsuno M
    Cardiol Ther; 2021 Dec; 10(2):289-311. PubMed ID: 34089151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
    Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
    J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
    Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
    Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.
    Brannagan TH; Auer-Grumbach M; Berk JL; Briani C; Bril V; Coelho T; Damy T; Dispenzieri A; Drachman BM; Fine N; Gaggin HK; Gertz M; Gillmore JD; Gonzalez E; Hanna M; Hurwitz DR; Khella SL; Maurer MS; Nativi-Nicolau J; Olugemo K; Quintana LF; Rosen AM; Schmidt HH; Shehata J; Waddington-Cruz M; Whelan C; Ruberg FL
    Orphanet J Rare Dis; 2021 May; 16(1):204. PubMed ID: 33957949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.